Actively Recruiting
Multicenter Randomized Study of Plonmarlimab Versus Betamethasone for Adults With Acute Gouty Arthritis Evaluating Efficacy, Safety, and Pharmacokinetics
Led by TJ Biopharma Co., Ltd. · Updated on 2026-10-15
170
Participants Needed
30
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of plonmarlimab in adults with acute gouty arthritis. This phase II, multicenter, randomized, double-blind, double-dummy, active-controlled study aims to compare plonmarlimab against an active comparator to understand its effects on pain reduction as measured by the Visual Analogue Scale VAS within 72 hours after dosing. An interim analysis after the first 60 participants will guide potential adjustments to sample size and treatment group selection. Participants are randomly assigned to one of three groups plonmarlimab 3 mgkg as a single intravenous infusion, plonmarlimab 6 mgkg as a single intravenous infusion, or compound betamethasone 7 mg as a single intramuscular injection. The study includes a double-dummy design with placebos matching both active treatments. The primary focus is on the initial single dose administration, with no further dosing detailed. Participants will be assessed for pain intensity using the VAS score at 72 hours after the initial dose. The study collects data on treatment safety, tolerability, pharmacokinetics, and immunogenicity. The trial duration and visit schedule beyond the primary outcome are not specified, but participants are monitored closely during the initial treatment period to evaluate study endpoints and safety.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
Research Team
L
Lina Qin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here